Brookline Capital Management Estimates RADX FY2026 Earnings

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Equities researchers at Brookline Capital Management lowered their FY2026 earnings per share estimates for Radiopharm Theranostics in a research report issued on Tuesday, September 2nd. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($4.81) per share for the year, down from their prior estimate of ($3.14). Brookline Capital Management has a “Buy” rating and a $18.00 price objective on the stock.

Separately, ThinkEquity upgraded Radiopharm Theranostics to a “strong-buy” rating in a report on Monday, May 12th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to data from MarketBeat.com, Radiopharm Theranostics presently has an average rating of “Strong Buy” and a consensus target price of $15.00.

Radiopharm Theranostics Stock Up 2.7%

Shares of RADX stock opened at $5.75 on Friday. The business has a 50 day simple moving average of $4.88. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $50.82.

Institutional Investors Weigh In On Radiopharm Theranostics

An institutional investor recently bought a new position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. acquired a new stake in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned 0.10% of Radiopharm Theranostics as of its most recent filing with the Securities & Exchange Commission.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.